Jonathon Lim

Shares of Ignyta Inc (NASDAQ: RXDX) were trading higher by more than 6 percent during Monday's pre-market session after the company announced that the FDA designated its entrectinib, a lead product candidate an Orphan Drug for the treatment of neuroblastoma. The FDA grants Orphan Drug...